Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02654691Completed

Chronic Neuropathy Following Chemotherapy

Role: collaborator

NCT02623764Unknown

EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors

Role: collaborator

NCT02273921Not ApplicableUnknown

EEG Classification System for Dementia

Role: lead

NCT02273895Not ApplicableCompleted

The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study

Role: lead

NCT02254213Completed

Intra-individual Stability in Electroencephalography (EEG) Parameters

Role: lead

All 5 trials loaded